Skip to main content
Erschienen in: Annals of Surgical Oncology 4/2009

01.04.2009 | Melanomas

Method of Detection of Initial Recurrence of Stage II/III Cutaneous Melanoma: Analysis of the Utility of Follow-Up Staging

verfasst von: Michael O. Meyers, MD, Jen Jen Yeh, MD, Jill Frank, MS, Patricia Long, FNP, Allison M. Deal, MS, Keith D. Amos, MD, David W. Ollila, MD

Erschienen in: Annals of Surgical Oncology | Ausgabe 4/2009

Einloggen, um Zugang zu erhalten

Abstract

Background

The follow-up of patients with cutaneous melanoma is controversial. Current recommendations suggest routine history and physical examination every 3 to 6 months for the first 3 years and correlate studies including laboratory tests and radiographic imaging. However, the utility of these recommendations are unclear. The purpose of this study was to determine the impact of routine imaging on the method of detection of first recurrence in patients with stage II and sentinel lymph node–positive stage III melanoma.

Methods

We analyzed a prospective database of all cutaneous melanoma patients treated at our institution from 1997 to 2005 who had at least 2 years of follow-up. The method of detection of initial recurrence was analyzed.

Results

One hundred eighteen patients with stage II (n = 83) or III (n = 35) melanoma who were followed for at least 2 years were identified. Forty-three of these patients developed recurrence (median time to recurrence, 14 months). Site of first recurrence was as follows: 4 local, 17 in transit, 7 regional lymph node, and 15 distant. Twenty-nine recurrences (67%) were either patient detected or symptomatic. Eleven (26%) were detected by the physician at routine follow-up. Only three (7%) were identified by imaging (two chest X-ray and one brain magnetic resonance imaging) in an otherwise asymptomatic patient.

Conclusions

Two-thirds of all initial recurrences of cutaneous melanoma were either detected by a patient or were symptomatic, with most of the remainder detected during routine physical examination. Routine imaging added little value in the detection of initial recurrence.
Literatur
1.
Zurück zum Zitat Shumate CR, Urist MM, Maddox WA. Melanoma recurrence surveillance. Patient or physician based? Ann Surg. 1995;221:566–9.PubMedCrossRef Shumate CR, Urist MM, Maddox WA. Melanoma recurrence surveillance. Patient or physician based? Ann Surg. 1995;221:566–9.PubMedCrossRef
2.
Zurück zum Zitat Poo-Hwu WJ, Ariyan S, Lamb L, et al. Follow-up recommendations for patients with American Joint Committee on Cancer stages I–III malignant melanoma. Cancer. 1999;86:2252–8.PubMedCrossRef Poo-Hwu WJ, Ariyan S, Lamb L, et al. Follow-up recommendations for patients with American Joint Committee on Cancer stages I–III malignant melanoma. Cancer. 1999;86:2252–8.PubMedCrossRef
3.
Zurück zum Zitat Garbe C, Paul A, Kohler-Spath H, et al. Prospective evaluation of a follow-up schedule in cutaneous melanoma patients: recommendations for an effective follow-up strategy. J Clin Oncol. 2003;21:520–9.PubMedCrossRef Garbe C, Paul A, Kohler-Spath H, et al. Prospective evaluation of a follow-up schedule in cutaneous melanoma patients: recommendations for an effective follow-up strategy. J Clin Oncol. 2003;21:520–9.PubMedCrossRef
4.
Zurück zum Zitat Francken AB, Bastiaannet E, Hoekstra HJ. Follow-up in patients with localised primary cutaneous melanoma. Lancet Oncol 2005;6:608–21.PubMedCrossRef Francken AB, Bastiaannet E, Hoekstra HJ. Follow-up in patients with localised primary cutaneous melanoma. Lancet Oncol 2005;6:608–21.PubMedCrossRef
5.
Zurück zum Zitat Francken AB, Shaw HM, Accortt NA, et al. Detection of first relapse in cutaneous melanoma patients: implications for the formulation of evidence-based follow-up guidelines. Ann Surg Oncol. 2007;14:1924–33.PubMedCrossRef Francken AB, Shaw HM, Accortt NA, et al. Detection of first relapse in cutaneous melanoma patients: implications for the formulation of evidence-based follow-up guidelines. Ann Surg Oncol. 2007;14:1924–33.PubMedCrossRef
6.
Zurück zum Zitat Nieweg OE, Kroon BB. The conundrum of follow-up: should it be abandoned? Surg Oncol Clin N Am. 2006;15:319–30.PubMedCrossRef Nieweg OE, Kroon BB. The conundrum of follow-up: should it be abandoned? Surg Oncol Clin N Am. 2006;15:319–30.PubMedCrossRef
7.
Zurück zum Zitat Weiss M, Loprinzi CL, Creagan ET, et al. Utility of follow-up tests for detecting recurrent disease in patients with malignant melanomas. JAMA. 1995;274:1703–5.PubMedCrossRef Weiss M, Loprinzi CL, Creagan ET, et al. Utility of follow-up tests for detecting recurrent disease in patients with malignant melanomas. JAMA. 1995;274:1703–5.PubMedCrossRef
8.
Zurück zum Zitat Dicker TJ, Kavanagh GM, Herd RM, et al. A rational approach to melanoma follow-up in patients with primary cutaneous melanoma. Scottish Melanoma Group. Br J Dermatol. 1999;140:249–54. Dicker TJ, Kavanagh GM, Herd RM, et al. A rational approach to melanoma follow-up in patients with primary cutaneous melanoma. Scottish Melanoma Group. Br J Dermatol. 1999;140:249–54.
9.
Zurück zum Zitat Cutaneous malignant melanoma. ESMO clinical recommendations for diagnosis, treatment and follow-up. Ann Oncol. 2007;18(Suppl 2):ii71–3. Cutaneous malignant melanoma. ESMO clinical recommendations for diagnosis, treatment and follow-up. Ann Oncol. 2007;18(Suppl 2):ii71–3.
10.
Zurück zum Zitat Hofmann U, Szedlak M, Rittgen W, et al. Primary staging and follow-up in melanoma patients—monocenter evaluation of methods, costs and patient survival. Br J Cancer. 2002;87:151–7.PubMedCrossRef Hofmann U, Szedlak M, Rittgen W, et al. Primary staging and follow-up in melanoma patients—monocenter evaluation of methods, costs and patient survival. Br J Cancer. 2002;87:151–7.PubMedCrossRef
12.
Zurück zum Zitat Swetter SM, Carroll LA, Johnson DL, et al. Positron emission tomography is superior to computed tomography for metastatic detection in melanoma patients. Ann Surg Oncol. 2002;9:646–53.PubMedCrossRef Swetter SM, Carroll LA, Johnson DL, et al. Positron emission tomography is superior to computed tomography for metastatic detection in melanoma patients. Ann Surg Oncol. 2002;9:646–53.PubMedCrossRef
13.
Zurück zum Zitat Friedman KP, Wahl RL. Clinical use of positron emission tomography in the management of cutaneous melanoma. Semin Nucl Med. 2004;34:242–53.PubMedCrossRef Friedman KP, Wahl RL. Clinical use of positron emission tomography in the management of cutaneous melanoma. Semin Nucl Med. 2004;34:242–53.PubMedCrossRef
14.
Zurück zum Zitat Antoch G, Saoudi N, Kuehl H, et al. Accuracy of whole-body dual-modality fluorine-18-2-fluoro-2-deoxy-d-glucose positron emission tomography and computed tomography (FDG-PET/CT) for tumor staging in solid tumors: comparison with CT and PET. J Clin Oncol. 2004;22:4357–68.PubMedCrossRef Antoch G, Saoudi N, Kuehl H, et al. Accuracy of whole-body dual-modality fluorine-18-2-fluoro-2-deoxy-d-glucose positron emission tomography and computed tomography (FDG-PET/CT) for tumor staging in solid tumors: comparison with CT and PET. J Clin Oncol. 2004;22:4357–68.PubMedCrossRef
15.
Zurück zum Zitat Reinhardt MJ, Joe AY, Jaeger U, et al. Diagnostic performance of whole body dual modality 18F-FDG PET/CT imaging for N- and M-staging of malignant melanoma: experience with 250 consecutive patients. J Clin Oncol. 2008;24:1178–87.CrossRef Reinhardt MJ, Joe AY, Jaeger U, et al. Diagnostic performance of whole body dual modality 18F-FDG PET/CT imaging for N- and M-staging of malignant melanoma: experience with 250 consecutive patients. J Clin Oncol. 2008;24:1178–87.CrossRef
16.
Zurück zum Zitat Clark PB, Soo V, Kraas J, et al. Futility of fluorodeoxyglucose F 18 positron emission tomography in initial evaluation of patients with T2 to T4 melanoma. Arch Surg. 2006;141:284–8.PubMedCrossRef Clark PB, Soo V, Kraas J, et al. Futility of fluorodeoxyglucose F 18 positron emission tomography in initial evaluation of patients with T2 to T4 melanoma. Arch Surg. 2006;141:284–8.PubMedCrossRef
17.
Zurück zum Zitat Yancovitz M, Finelt N, Warycha MA, et al. Role of radiologic imaging at the time of initial diagnosis of stage T1b–T3b melanoma. Cancer. 2007;110:1107–14.PubMedCrossRef Yancovitz M, Finelt N, Warycha MA, et al. Role of radiologic imaging at the time of initial diagnosis of stage T1b–T3b melanoma. Cancer. 2007;110:1107–14.PubMedCrossRef
19.
Zurück zum Zitat Francken AB, Accortt NA, Shaw HM, et al. Prognosis and determinants of outcome following locoregional or distant recurrence in patients with cutaneous melanoma. Ann Surg Oncol. 2008. DOI:10.1245/s10434-007-9717-9 Francken AB, Accortt NA, Shaw HM, et al. Prognosis and determinants of outcome following locoregional or distant recurrence in patients with cutaneous melanoma. Ann Surg Oncol. 2008. DOI:10.​1245/​s10434-007-9717-9
20.
Zurück zum Zitat Fusi S, Ariyan S, Sternlicht A. Data on first recurrence after treatment for malignant melanoma in a large patient population. Plast Reconstr Surg. 1993;91:94–8.PubMedCrossRef Fusi S, Ariyan S, Sternlicht A. Data on first recurrence after treatment for malignant melanoma in a large patient population. Plast Reconstr Surg. 1993;91:94–8.PubMedCrossRef
21.
Zurück zum Zitat Francken AB, Thompson JF, Bastiaannet E, et al. Detection of the first recurrence in patients with melanoma: three quarters by the patient, one quarter during outpatient follow-up. Ned Tijdschr Geneeskd. 2008;152:557–62.PubMed Francken AB, Thompson JF, Bastiaannet E, et al. Detection of the first recurrence in patients with melanoma: three quarters by the patient, one quarter during outpatient follow-up. Ned Tijdschr Geneeskd. 2008;152:557–62.PubMed
22.
Zurück zum Zitat Buzzell RA, Zitelli JA. Favorable prognostic factors in recurrent and metastatic melanoma. J Am Acad Dermatol. 1996;34(5 Pt 1):798–803. Buzzell RA, Zitelli JA. Favorable prognostic factors in recurrent and metastatic melanoma. J Am Acad Dermatol. 1996;34(5 Pt 1):798–803.
23.
Zurück zum Zitat Ollila DW. Complete metastasectomy in patients with stage IV metastatic melanoma. Lancet Oncol. 2006;7:919–24.PubMedCrossRef Ollila DW. Complete metastasectomy in patients with stage IV metastatic melanoma. Lancet Oncol. 2006;7:919–24.PubMedCrossRef
24.
Zurück zum Zitat Phan GQ, Attia P, Steinberg SM, et al. Factors associated with response to high-dose interleukin–2 in patients with metastatic melanoma. J Clin Oncol. 2001;19:3477–82.PubMed Phan GQ, Attia P, Steinberg SM, et al. Factors associated with response to high-dose interleukin–2 in patients with metastatic melanoma. J Clin Oncol. 2001;19:3477–82.PubMed
25.
Zurück zum Zitat Kaufmann R, Spieth K, Leiter U, et al. Temozolomide in combination with interferon-alfa versus temozolomide alone in patients with advanced metastatic melanoma: a randomized, phase III, multicenter study from the Dermatologic Cooperative Oncology Group. J Clin Oncol. 2005;23:9001–7.PubMedCrossRef Kaufmann R, Spieth K, Leiter U, et al. Temozolomide in combination with interferon-alfa versus temozolomide alone in patients with advanced metastatic melanoma: a randomized, phase III, multicenter study from the Dermatologic Cooperative Oncology Group. J Clin Oncol. 2005;23:9001–7.PubMedCrossRef
Metadaten
Titel
Method of Detection of Initial Recurrence of Stage II/III Cutaneous Melanoma: Analysis of the Utility of Follow-Up Staging
verfasst von
Michael O. Meyers, MD
Jen Jen Yeh, MD
Jill Frank, MS
Patricia Long, FNP
Allison M. Deal, MS
Keith D. Amos, MD
David W. Ollila, MD
Publikationsdatum
01.04.2009
Verlag
Springer-Verlag
Erschienen in
Annals of Surgical Oncology / Ausgabe 4/2009
Print ISSN: 1068-9265
Elektronische ISSN: 1534-4681
DOI
https://doi.org/10.1245/s10434-008-0238-y

Weitere Artikel der Ausgabe 4/2009

Annals of Surgical Oncology 4/2009 Zur Ausgabe

Head and Neck Oncology

In Reply

Update Chirurgie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

S3-Leitlinie „Diagnostik und Therapie des Karpaltunnelsyndroms“

Karpaltunnelsyndrom BDC Leitlinien Webinare
CME: 2 Punkte

Das Karpaltunnelsyndrom ist die häufigste Kompressionsneuropathie peripherer Nerven. Obwohl die Anamnese mit dem nächtlichen Einschlafen der Hand (Brachialgia parästhetica nocturna) sehr typisch ist, ist eine klinisch-neurologische Untersuchung und Elektroneurografie in manchen Fällen auch eine Neurosonografie erforderlich. Im Anfangsstadium sind konservative Maßnahmen (Handgelenksschiene, Ergotherapie) empfehlenswert. Bei nicht Ansprechen der konservativen Therapie oder Auftreten von neurologischen Ausfällen ist eine Dekompression des N. medianus am Karpaltunnel indiziert.

Prof. Dr. med. Gregor Antoniadis
Berufsverband der Deutschen Chirurgie e.V.

S2e-Leitlinie „Distale Radiusfraktur“

Radiusfraktur BDC Leitlinien Webinare
CME: 2 Punkte

Das Webinar beschäftigt sich mit Fragen und Antworten zu Diagnostik und Klassifikation sowie Möglichkeiten des Ausschlusses von Zusatzverletzungen. Die Referenten erläutern, welche Frakturen konservativ behandelt werden können und wie. Das Webinar beantwortet die Frage nach aktuellen operativen Therapiekonzepten: Welcher Zugang, welches Osteosynthesematerial? Auf was muss bei der Nachbehandlung der distalen Radiusfraktur geachtet werden?

PD Dr. med. Oliver Pieske
Dr. med. Benjamin Meyknecht
Berufsverband der Deutschen Chirurgie e.V.

S1-Leitlinie „Empfehlungen zur Therapie der akuten Appendizitis bei Erwachsenen“

Appendizitis BDC Leitlinien Webinare
CME: 2 Punkte

Inhalte des Webinars zur S1-Leitlinie „Empfehlungen zur Therapie der akuten Appendizitis bei Erwachsenen“ sind die Darstellung des Projektes und des Erstellungswegs zur S1-Leitlinie, die Erläuterung der klinischen Relevanz der Klassifikation EAES 2015, die wissenschaftliche Begründung der wichtigsten Empfehlungen und die Darstellung stadiengerechter Therapieoptionen.

Dr. med. Mihailo Andric
Berufsverband der Deutschen Chirurgie e.V.